11月20日万泰生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘折 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 23.10 | 1307.46 | 56.60 | 6.05 | 西部证券股份有限公司深圳 | 浙商证券股份有限 | | | | | | 深南大道证券营业部 | 公司深圳分公司 | | 17.50 | 990.50 | 56.60 | 6.05 | 广发证券股份有限公司广州 | 浙商证券股份有限 | | | | | | 临江大道证券营业部 | 公司深圳分公司 | | 11.00 | 622.60 | 56.60 | 6.05 | 浙商证券股份有限公司深圳 | 浙商证券股份有限 | | | | | | 分公司 | 公司深圳分公司 | （文章来源：证券时报网） 据天眼查APP显示，北京万泰生物药业股份有限公司成立于1991年04月23日，注册资本126512.2774万 人民币。（数据宝） 万泰生物11月20 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603717 证券简称：天域生物 公告编号：2025-106 天域生物科技股份有限公司关于 变更保荐机构后重新签订募集资金 三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）于2025年10月25日披露了《关于变更保荐机构及保荐代 表人的公告》（公告编号：2025-099），公司因聘请国海证券股份有限公司（以下简称"国海证券"）担 任公司2025年度向特定对象发行A股股票事项的保荐机构，原保荐机构中德证券有限责任公司尚未完成 的持续督导工作由国海证券承接。为规范募集资金管理，保护投资者利益，根据《上市公司募集资金监 管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第1号一一规范运 作》等有关法律、法规和规范性文件的规定，公司于近日与国海证券、南洋商业银行（中国）有限公司 上海分行重新签订了《募集资金专户存储三方监管协议》。现将有关情况公告如下： 一、募集资金基本情况 经中国证券监督 ...

证券日报网讯安科生物（300009）11月20日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司的股东总数为76058户。 ...

Group 1 - The company has obtained EU CE-IVDR certification and is exporting to multiple EU countries, including Croatia, Italy, Slovakia, and Hungary [2]

证券日报网讯 博雅生物11月20日在互动平台回答投资者提问时表示，公司股票价格受宏观环境、行业 政策、投资者风险偏好等诸多因素影响。公司一直努力经营，提升盈利能力，实施稳健的分红政策，积 极回报股东。截至目前，公司未有股份回购的计划。 （编辑 袁冠琳） ...

证券之星消息，11月20日生物制品板块较上一交易日下跌0.54%，博晖创新领跌。当日上证指数报收于 3931.05，下跌0.4%。深证成指报收于12980.82，下跌0.76%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920047 | 诺思兰德 | 26.00 | 3.54% | 3.88万 | | 1.01亿 | | 688293 | 奧浦迈 | 58.95 | 2.22% | 1.22万 | | 7170.35万 | | 688331 | 荣昌生物 | 88.89 | 1.40% | 3.27万 | | 2.91亿 | | 300142 | 沃森生物 | 12.54 | 1.37% | 54.60万 | | 6.97亿 | | 616889 | 欧林生物 | 22.80 | 1.11% | 2.28万 | | 5169.70万 | | 688136 | 科兴制药 | 33.70 | 0.60% | 1.30万 | | 4387.18万 | ...

天眼查App显示，近日，徐州罄桃生物科技有限公司成立，法定代表人为周莹莹，注册资本300万人民 币，经营范围为许可项目：茶叶制品生产；生产加工边销茶；饮料生产；食品生产；食品销售；食品互 联网销售；林木种子生产经营（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营 项目以审批结果为准）一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广； 生物基材料技术研发；中药提取物生产；传统香料制品经营；茶叶种植；金花茶人工培植；中草药种 植；地产中草药（不含中药饮片）购销；互联网销售（除销售需要许可的商品）（除依法须经批准的项 目外，凭营业执照依法自主开展经营活动）。 ...

Group 1: Financial Market Overview - The A-share market experienced a general adjustment with all major indices declining, with the STAR 50 index showing the largest drop of 2.13% [2] - As of November 18, the margin trading balance in the two markets was 24,948.32 billion yuan, a decrease of 25.67 billion yuan from the previous week [2] - The average daily number of investors participating in margin trading decreased by 3.91% to 437,462 [2] Group 2: Industry Insights - Machinery and Equipment - In October, the production of industrial robots in China increased by 17.90% year-on-year, with a monthly output of 57,900 units, and the cumulative output for the first ten months reached approximately 602,700 units, a year-on-year increase of 28.80% [8] - The construction machinery sector is expected to maintain growth due to favorable downstream demand driven by infrastructure projects and a reduction in tariff disturbances [7][8] - The mechanical equipment industry is rated as "optimistic," with a focus on domestic brands gaining market share [5][8] Group 3: Pharmaceutical and Biological Industry Performance - In Q3 2025, the pharmaceutical and biological industry saw a recovery in revenue and net profit, with a notable increase in gross and net profit margins [9] - The chemical pharmaceutical sector reported a revenue of 1237.44 billion yuan, with a net profit of 114.64 billion yuan, reflecting a significant improvement in profitability [9][10] - The medical device sector showed signs of recovery, with Q3 revenue reaching 604.49 billion yuan, although net profit decreased by 5.1% year-on-year [11]

Core Viewpoint - The company has signed a strategic cooperation agreement with Bank of China Sichuan Branch, committing to provide a total of no less than 8 billion RMB in comprehensive credit support [1] Group 1: Strategic Cooperation - The agreement focuses on deep cooperation in domestic and international capital market operations, cross-border finance, and international business collaboration [1] - The partnership will also explore innovative financial services and industry chain finance, as well as personal financial services [1] Group 2: Agreement Details - The agreement becomes effective upon the signatures and seals of the legal representatives of both parties and has a validity period of five years, automatically extending upon expiration [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.47% on November 19, with Jindike leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Individual Stock Performance - Notable gainers included *ST Sihuan, which rose by 1.15% to a closing price of 2.63, and Teabo Bio, which increased by 0.91% to 77.78 [1] - Significant decliners included Jindike, which fell by 6.60% to 25.03, and Hualan Store, down 5.98% to 22.80 [2] Trading Volume and Value - The trading volume and value for key stocks in the biopharmaceutical sector were highlighted, with Anke Bio recording a volume of 210,100 hands and a transaction value of 218 million [1] - Jindike had a trading volume of 95,600 hands and a transaction value of 237 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 911 million from institutional investors, while retail investors contributed a net inflow of 845 million [2] - The capital flow for individual stocks showed that Changchun High-tech had a net inflow of 8.84 million from institutional investors, while it experienced a net outflow of 10.70 million from speculative funds [3]